Impressive growth, high world rankings and excellent impact factors demonstrate strength of Informa Healthcare’s comprehensive portfolio of highly respected publications.
LONDON – Monday, 29 June 2009 – Informa Healthcare – one of the world’s leading medical and scientific publishing groups – has announced highlights of its latest journal Impact Factor results, with impressive results across the division’s comprehensive range of titles. The company’s highly respected range of Expert Opinion titles performed notably well, with significant jumps for Expert Opinion on Biological Therapy which is up almost 20% to 3.475 and Expert Opinion on Therapeutic Targets, up more than 21% to 4.038. Expert Opinion on Investigational Drugs leads the series with a 2008 Impact Factor of 4.058 and two new titles – Expert Opinion on Drug Safety and Expert Opinion on Metabolism & Toxicology, registered sensational first ever Impact Factors of 3.073 and 3.069, respectively.
The company’s Critical Reviews in Toxicology also registered an outstanding impact factor of 7.204, up more than 40% and now ranked 2nd out of 75 journals in toxicology – with 1st place being an annual publication as compared with Critical Reviews in Toxicology’s ten issues per year.
Impact factors are a method of measuring the influence which a journal has on the scientific community. They are calculated by Thomson Reuters and are designed to indicate how many times the published articles of a journal are cited during the course of a year, providing an insight to how much ‘impact’ the journal is making on its audiences.
“Impact Factors provide us with a measure for the importance of our journals to the medical and scientific communities we serve,” explains Phil Garner, Publishing Director at Informa Healthcare. “We are delighted with the performance of our market leading titles as well as some new journals which have posted excellent first time results.”
“Our Expert Opinion range of titles – which provides in-depth analysis of the pharmaceutical R&D pipeline – has registered impressive gains across the board and first ever Impact Factors of above three for our two new titles is testament to the quality of information that goes into our journals,” says Phil. “These results give a big ‘thumbs up’ to the comprehensive, intelligent content which make these titles the definitive reference source for leading pharmaceutical scientists.”
Other Informa Healthcare journals that have performed well are the Journal of Drug Targeting – up to 2.771, Inhalation Toxicology – up to 2.403, International Reviews of Immunology with a 37% increase to 4.935, the International Journal of Radiation Biology – up 48% to 2.178, and first ever IF’s for The Aging Male – at 2.622, and Prehospital Emergency Care at 1.248, now ranked in the top half of 13 journals in the emergency medicine category.
Informa’s Scandinavian titles also performed well: Fifteen out of twenty five registered increased impact factors and eighteen with impact factors of over 1.00. The International Journal of Pediatric Obesity registered 3.984 in just its second year, up almost 100% from 2.00 in 2000. World Journal of Biological Psychiatry was also up by more than 111% to 3.582. The division’s flagship journal, Annals of Medicine, registered an impact factor of 5.435 with some 78% of the group’s Scandinavian journals registering impact factors.
“We are justifiably proud of the performance of all of our journals,” adds Phil. “Our new titles have done very well and our established journals have continued to go from strength to strength, with an impressive number of them moving many places up in their respective rankings.”
Informa’s results, across its wide range of journals, are remarkable: The International Journal on the Biology of Stress is up to 2.952; The Journal of Protein Folding Disorders is up to 1.714; The International Journal of Audiology has an Impact Factor of 1.201; The Journal of Psychosomatic Obstetrics and Gynecology is up 67% to 1.585, and Platelets is up to 2.271 – a rise of almost 20% over last year. In addition, the Journal of Intellectual & Developmental Disability has increased to 0.902 and Pathology to 2.324.
“Our overall performance – together with the outstanding individual performances of many of our titles – ensures that Informa continues to serve as a leading force in medical and scientific publishing, providing the market with the lion’s share of must-read titles,” explains Phil.
Monday, 29 June 2009
Wednesday, 17 June 2009
Scholar One 'submitting agent' feature activated for Expert Opinion journals
Medical communication agencies can now submit manuscripts to Expert Opinion journals as third party, on behalf of the authors .
The name of the submitting agent will not appear in the authors' list and both the submitting agent and the corresponding author will receive emails from the editorial team regarding the manuscript.
The submitting person must now identify itself as an author or a third-party submitting agent at the first step of the submission process.
This feature has been activated for the following journals using the Scholar One submission platform:
The name of the submitting agent will not appear in the authors' list and both the submitting agent and the corresponding author will receive emails from the editorial team regarding the manuscript.
The submitting person must now identify itself as an author or a third-party submitting agent at the first step of the submission process.This feature has been activated for the following journals using the Scholar One submission platform:
- Expert Opinion on Pharmacotherapy
- Expert Opinion on Therapeutic Targets
- Expert Opinion on Investigational Drugs
- Expert Opinion on Biological Therapy
- Expert Opinion on Metabolism and Toxicology
- Expert Opinion on Drug Safety
Subscribe to:
Posts (Atom)
